Washington’s 340B Law Takes Effect After Judge Denies Injunction
Market Access Intelligence — June 12, 2026
A federal judge let Washington’s 340B contract pharmacy law take effect June 10, denying PhRMA, AbbVie, Novartis, and AstraZeneca the injunction they sought — the same week the FDA cleared the first interchangeable Simponi (golimumab) biosimilars and New York’s 340B antidiscrimination bill died at session’s end.
Today’s top developments:
- A federal judge denied the manufacturers’ preliminary injunction, letting Washington’s SB 5981 contract pharmacy law take effect June 10 (340B Report)
- HRSA declined to appeal the ruling that struck down its 340B hospital drug purchasing restrictions policy, the same day the administration nominated a 340B critic for HHS Assistant Secretary (340B Report)
- The FDA approved Immgolis and Immgolis Intri, the first interchangeable biosimilars to Janssen’s Simponi (golimumab), opening the ~$2B franchise to competition (Center for Biosimilars)
What to Watch
- Washington 340B enforcement — will manufacturers comply or escalate? With the preliminary injunction denied and the law in effect, the four litigating manufacturers (PhRMA, AbbVie, Novartis, AstraZeneca) face a decision: comply (following GSK’s example), escalate to the 9th Circuit (which is unlikely to rule before the law has been in effect for months), or absorb $5,000-per-day-per-violation civil penalties pending appeal. The Washington AG’s enforcement posture will determine whether covered entities see immediate operational benefits or whether enforcement timelines stretch into 2027. Other states with pending 340B laws are watching closely.
- Johns Hopkins nominee confirmation hearing — The Senate confirmation process for the HHS Assistant Secretary nominee will test whether 340B advocates can derail or modify the nomination. Senate HELP Committee dynamics will be critical, particularly given the bipartisan opposition to the 340B rebate model that has produced 94+ House signatories and 8 Senate Democrats. Watch for whether covered entity associations mobilize against the nomination and whether the Senator’s reform allies see the nominee as advancing their broader agenda or risking program-disruption optics in the midterm cycle.
- Adam Fein’s June 12 340B webinar — market structure framing for the next phase — DCI’s “340B in 2026: Market Shifts, Policy Battles” webinar today (June 12) will likely synthesize the rerun analyses (80% PBM concentration, 77% contract pharmacy concentration, Minnesota $1B excess) into a unified narrative for use in upcoming Congressional and HRSA debates. Fein’s framing will heavily influence how manufacturer trade associations, hospital groups, and Congressional staff understand the program’s economics going into Q3 2026 reform negotiations.
This brief highlights today’s top stories. Read the full June 12, 2026 edition → for all stories, source links, and analysis.
